DDrare: Database of Drug Development for Rare Diseases

22. もやもや病
［臨床試験数：11，薬物数：18（DrugBank：11），標的遺伝子数：28，標的パスウェイ数：43］

Searched query = "Moyamoya disease", "Occlusive disease in circle of Willis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = Aspirin; Butylphthalide; Desflurane; Device: Magnetic Resonance Imaging; Device: RIC; Dl-3-n-butylphthalide (NBP); Edaravone; Erythropoietin; Gadobutrol; Gadovist; Norepinephrine; Normal Saline 0.9% Infusion Solution; Normal saline; Phenylephrine; Propofol; Sevoflurane; Xenon; Xenon contrast agent

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03882060 (ClinicalTrials.gov)	April 8, 2019	12/3/2019	Effect of Recombinant Human EPO on the Postoperative Neurologic Outcome in Pediatric Moyamoya Patients	The Effect of Recombinant Human Erythropoietin on the Postoperative Neurologic Outcome in Pediatric Moyamoya Disease Patients - A Double Blind Randomized Controlled Trial	Moyamoya Disease;Pediatrics;Cerebrovascular Disorders	Drug: erythropoietin;Drug: Normal saline	Seoul National University Hospital	NULL	Recruiting	N/A	18 Years	All	82	N/A	Korea, Republic of
2	NCT03162588 (ClinicalTrials.gov)	May 1, 2010	18/5/2017	Multiple Burrhole Therapy With Erythropoietin for Unstable Moyamoya	Feasibility Study of Multiple Burrhole Therapy Combined With Intravenous Erythropoietin Pretreatment for Unstable Moyamoya	Ischemic Attack;Ischemic Stroke;Moyamoya Disease;Burr Hole;Angiogenesis	Drug: erythropoietin	Ajou University School of Medicine	NULL	Completed	16 Years	N/A	All	37	Phase 1;Phase 2	Korea, Republic of

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT03882060
(ClinicalTrials.gov)

April 8, 2019

12/3/2019

Effect of Recombinant Human EPO on the Postoperative Neurologic Outcome in Pediatric Moyamoya Patients

The Effect of Recombinant Human Erythropoietin on the Postoperative Neurologic Outcome in Pediatric Moyamoya Disease Patients - A Double Blind Randomized Controlled Trial

Moyamoya Disease;Pediatrics;Cerebrovascular Disorders

Drug: erythropoietin;Drug: Normal saline

Seoul National University Hospital

NULL

Recruiting

N/A

18 Years

All

N/A

Korea, Republic of

NCT03162588
(ClinicalTrials.gov)

May 1, 2010

18/5/2017

Multiple Burrhole Therapy With Erythropoietin for Unstable Moyamoya

Feasibility Study of Multiple Burrhole Therapy Combined With Intravenous Erythropoietin Pretreatment for Unstable Moyamoya

Ischemic Attack;Ischemic Stroke;Moyamoya Disease;Burr Hole;Angiogenesis

Drug: erythropoietin

Ajou University School of Medicine

NULL

Completed

16 Years

N/A

All

Phase 1;Phase 2

Korea, Republic of